Efficacy and safety of remimazolam in elective general anesthesia in hypertensive patients: a single-center, randomized, controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000040579

Enrollment

Unknown

Registered

2020-12-03

Start date

2021-03-01

Completion date

Unknown

Last updated

2021-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension

Interventions

propofol:injection propofol for induction: 40mg/kg/h

for maintenance 6-8mg/kg/h

remimazolam:injection remimazolam for induction: 6mg/kg/h

for maintenance 1-3mg/kg/h

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) aged >=18 years; 2) ASA(American Society of Anesthesiologists)<=III; 3) Patients meet the diagnostic criteria for hypertension

Exclusion criteria

Exclusion criteria: 1) Allergic to remimazolam and propofol; 2) A history of drug abuse; 3) With craniocerebral injury or intracranial hypertension; 4) A history of mental illness; 5) With myasthenia gravis

Design outcomes

Primary

Measure	Time frame
Blood Pressure;Heart rate;BIS;Incidence of hypotension or hypertension;Incidence of tachycardia or bradycardia;	—

Secondary

Measure	Time frame
Induction and recovery time;Incidence of excessive or shallow sedation;Incidence of injection pain;Anaesthesia satisfaction;Other adverse reactions;	—

Countries

China

Contacts

Public ContactHuang Yaqi

982008926@qq.com+86 13665074122

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026